Advertisement

Topics

Latest "Placebo Hepatitis Virus Infection" News Stories

12:32 EDT 19th October 2017 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 5,300+

Extremely Relevant

An update on the management of chronic hepatitis B and C infection

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-a...


Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

Researchers identify how class of drugs blocks Hepatitis C virus replication

Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV). Over decades of infection, chronic HCV infection results in progressive damage to the liver and an increased risk for end stage liver disease and liver cancer, making the virus the leading cause of liver-related deaths in the United States today.


[Correspondence] New hepatitis C antiviral treatments eliminate the virus

The Cochrane Collaboration has published a topical systematic review1 and meta-analysis on direct-acting antivirals (DAA) for chronic hepatitis C virus (HCV) infection. Jakobsen and colleagues1 compared the results of randomised trials of any HCV DAA regimen versus no intervention or placebo. Their review reported data from 138 trials, which included 25 232 participants and encompassed all drugs...

Japan Approves 8-Week Treatment for Genotype 1 and 2 Hepatitis C Virus

NewsEnanta announces that AbbVie’s Maviret glecaprevir/pibrentasvir received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis C. Japan has one of the highest rates of hepatitis C virus infection in the industrialized world.

Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome

Sjögren’s is a chronic autoimmune disease characterized by dry mouth and eyes, fatigue, and musculoskeletal pain resulting from the attack of the moisture-producing glands by the body’s own white blood cells. The subject invention is based on the discovery of an association between infection by a novel clade 1 variant of hepatitis delta virus (HDV) and primary Sjögren’s syndrome.Read more

The 8-Week Cure for Hepatitis C

In less than a month, the FDA approved a second medication for hepatitis C virus (HCV) infection. The newer entry into the treatment arena is the first drug capable of suppressing viral load to undetectable levels in only 8 weeks.

Interventions for reducing hepatitis C infection in people who inject drugs

(University of Bristol) The first global review to quantify the impact of needle syringe programmes (NSP) and opioid substitution treatment (OST) in reducing the risk of becoming infected with the hepatitis C virus is published in Cochrane Library Drug and Alcohol Review Group and the journal Addiction. The study, has implications for millions of people who are 'at risk' from infection.

Three or More Cups of Coffee Daily Cuts Mortality Risk in Patients With Concurrent HIV and HCV

Patients infected by both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at specific risk of end-stage liver disease and greater risk of cardiovascular diseases and cancer. In addition, HIV infection accelerates the progression of chronic hepatitis C to fibrosis and development of cirrhosis and end-stage liver disease. In these

Scientists step closer to drug treatment for hepatitis B

A major new insight into how Hepatitis B Virus works could pave the way for new drug treatments for the infection which is the major cause of liver cancer worldwide.

ECDC report: Ten-fold increase of hepatitis E cases in the EU/EEA between 2005 and 2015

The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.

Combination Drug for HCV Infection

A new 3-drug combination medication for adults with chronic hepatitis C virus (HCV) infection has received FDA approval. The drug is indicated for patients with any of 6 viral genotypes who have either no cirrhosis or only a mild case of the liver disease.

Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma

CDC scientists have developed a novel enzyme immunoassay for the simultaneous detection of hepatitis C virus (HCV) core antigen and circulating HCV antibodies. Serological testing procedures for HCV circulating antibodies are well established. There is, however, a window of time between HCV infection and seroconversion that generates an opportunity for false negative results. This period varies fr...

Nine in 10 people unaware they have hepatitis

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with an emphasis that much work is left to be done to combat the viral infection. The organisation called for national responses towards hepatitis elimination to be accelerated and suggested that, at best, only one in 10 people were aware that they had the illness. In further cause of con...

Scientists a step closer to drug treatment for hepatitis B

A major new insight into how hepatitis B virus works could pave the way for new drug treatments for the infection which is the major cause of liver cancer worldwide, report scientists.

AbbVie’s Maviret approved in Europe for chronic hepatitis C

AbbVie’s maviret (glecaprevir/pibrentasvir) has secured the approval of the European Commission for the treatment of chronic hepatitis C virus (HCV) infection in all major genotypes from GT1 to GT6 in adult patients.

Lion TCR Pte Ltd. Release: Breakthrough Immunotherapy For Chronic Hepatitis B Virus Infection

  Life Sciences Jobs   ...

Lion TCR Release: Breakthrough Immunotherapy For Chronic Hepatitis B Virus Infection

  Life Sciences Jobs   ...

Around 9 million Europeans are affected by chronic hepatitis B or C

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed. On the occasion of World Hepatitis Day on 28 July, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevent...

[Articles] Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study

Semen alterations early after acute Zika virus infection might affect fertility and could be explained by virus effects on the testis and epididymis. Frequency of shedding and high viral load in semen, together with the presence of replicative virus in a motile spermatozoa fraction, can lead to Zika virus transmission during sexual contact and assisted reproduction procedures. Whole blood seems to...

China Food and Drug Administration Approves Gilead's Sovaldi (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection

- Sovaldi-based Regimens Demonstrated High Rates of Sustained Virologic Response or Cure for Chinese Hepatitis C Infected Patients - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the C...

ECDC report: 10-fold increase of hepatitis E cases in the EU/EEA in the last 10 years

(European Centre for Disease Prevention and Control (ECDC) ) The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.

DAAs for HCV in Patients With Severe Renal Impairment

Can direct-acting antivirals be used safely for treating hepatitis C virus infection in patients with severe renal impairment? Journal of Viral Hepatitis

ECDC report: 10-fold increase of hepatitis E cases in the EU/EEA between 2005 and 2015

(European Centre for Disease Prevention and Control (ECDC) ) The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.

Merck & Co. To Present New Data On ZEPATIER (Elbasvir And Grazoprevir) For The Treatment Of Chronic Hepatitis C Virus Infection At

  Life Sciences Jobs   ...


Quick Search
Advertisement
 

News Quicklinks